ArticleTranslational cancer research2022
High expression of ceramide synthase 5 predicts a poor prognosis in gastric cancer.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Integrative Multi-omics Analysis for Prioritization of Candidate Genes in Polycystic Ovary Syndrome.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Comprehensive bioinformatics analysis targeting sphingosine-related genes in head and neck cancer.Discover oncology · 2026Article
- High expression of TMEM119 predicts a poor prognosis in gastric cancer.Translational cancer research · 2026Article
- A sphingolipid rheostat controls apoptosis versus apical cell extrusion as alternative tumour-suppressive mechanisms.Cell death & disease · 2024Article
- The ceramide synthase (CERS/LASS) family: Functions involved in cancer progression.Cellular oncology (Dordrecht, Netherlands) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer is one of the most common malignant tumors worldwide. Ceramide synthase 5 (CerS5) is a member of the CerS family. Emerging evidence has shown that overexpressed CerS5 is correlated with the poor prognosis of cancer patients. However, the role of CerS5 in gastric cancer remains unclear. The aim of this study is to delineate the relevance of CerS5 levels to gastric cancer. Methods: The expression level of CerS5 was determined by immunohistochemistry, and the survival data of gastric cancer patients were obtained by regular follow-up. The gene expression profile of Results: Immunohistochemistry (IHC) staining indicated that CerS5 is overexpressed in gastric cancer tissues and metastatic lymph nodes. The levels of CerS5 were correlated with tumor location and carbohydrate antigen 50 (CA50). Moreover, the increased Conclusions: CerS5 is universally overexpressed in gastric cancer tissues and is an independent factor of poor prognosis for gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.